Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab or Olaratumab in Recurrent Glioblastoma
NCT00895180Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2010
- Primary completion
- Jun 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of olaratumab, ramucirumab in glioblastoma multiforme (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2010; status: completed.
02
Drugs
olaratumabramucirumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00895180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00895180.